| Literature DB >> 8691426 |
T Fukami1, T Yamakawa, K Niiyama, H Kojima, Y Amano, F Kanda, S Ozaki, T Fukuroda, M Ihara, M Yano, K Ishikawa.
Abstract
Continuing studies on modifications of potent cyclic pentapeptide endothelin (ET) receptor antagonists, represented by BQ-123, and potent linear tripeptide derivative ET receptor antagonists, represented by BQ-788, are described herein. The introduction of D-tryptophan analogues with C-2 substituents in these peptidic ET antagonists resulted in potent ET receptor antagonists with various ETA/ETB subtype selectivity. Combined ETA/ETB receptor antagonists were found in both cyclic pentapeptide and linear tripeptide series with 2-halo- and 2-methyl-D-tryptophans. In contrast, compounds with 2-cyano-D-tryptophan were ETB receptor-selective antagonists. The C-2 substituent of the D-tryptophanyl residue appeared to be very important for the discrimination of ETA/ETB subtype selectivity of the antagonists. The potent ET receptor antagonists with various ETA/ETB subtype selectivity synthesized in this study may be useful tools for elucidating the physiological and pathophysiological roles of ET and ET receptors.Entities:
Mesh:
Substances:
Year: 1996 PMID: 8691426 DOI: 10.1021/jm9600914
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446